Dr. Michael A. Vogelbaum, MD

Dr. Vogelbaum practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Vogelbaum's NPI, 1598732380, was assigned on March 1, 2006. Dr. Vogelbaum graduated from UVA School of Medicine in 1992. Dr. Vogelbaum holds Florida license ME138367.

Dr. Vogelbaum's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Vogelbaum's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Vogelbaum to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vogelbaum practices, 2 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Vogelbaum's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Vogelbaum is board certified in neurological surgery by the American Board of Neurological Surgery. Dmand AI has Dr. Vogelbaum's licenses on file in 8 states: Florida, Missouri, Michigan, Ohio, New York, Connecticut, Pennsylvania and Illinois.

Dmand AI lists craniotomy among the conditions Dr. Vogelbaum treats.

CMS data shows 54 Medicare services from Dr. Vogelbaum across 4 procedure codes in 2022, for 29 Medicare patients. Medicare paid $40,934 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 29 Medicare patients who saw Dr. Vogelbaum in 2024. The largest group is 65 to 74, with 16 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vogelbaum's median patient age at 66, with 53% women.

In 2018, Dr. Vogelbaum wrote 16 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $396 in total drug cost. In 2016, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Vogelbaum for performance year 2024, reported as part of a group. Dr. Vogelbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 280 papers to Dr. Vogelbaum, published from 2006 to 2025. 2017 was the busiest year, with 15. The most frequent topics are Brain Neoplasms, Radiosurgery and Glioblastoma. Dr. Vogelbaum has published most often in Neuro Oncol. Dr. Vogelbaum's most frequent co-authors are Gene Henry Barnett, MD, Samuel T. Chao, MD and Manmeet Singh Ahluwalia, MD.

Dmand AI links Dr. Vogelbaum to 14 clinical trials, 4 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Glioblastoma, Central Nervous System Neoplasms and Brain Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 3.

CMS Open Payments shows 42 general payments to Dr. Vogelbaum from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Alexion Pharmaceuticals, Inc. paid the most, $29,614.

Dmand AI lists 4 awards for Dr. Vogelbaum, most recently Regional Top Doctor in 2014.

Dr. Vogelbaum graduated from UVA School of Medicine in 1992. Dr. Vogelbaum is a member of AANS, ACS and CNS.

Dr. Vogelbaum is in network with 9 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.